论文部分内容阅读
本文应用荧光偏振免疫方法，采用特异性单克隆重试剂盒测定口服ＣｓＡ１２ｈ后全血ＣｓＡ的谷浓度，对１９９２年４月～１９９４年４月接受标准三联免疫治疗（ＣｓＡ＋ＡＺＰ＋Ｐｒｅｄ）的３１４例肾移植受者进行研究，连续测定１０３４次全血ＣｓＡ谷浓度和相应时间该患者的血肌酐、尿素氮和肝功能，以观察其临床有效性和安全性，结果提示：接受标准三联免疫治疗的肾移植受者，术后３个月、３～６个月和６个月以上ＣｓＡ血谷浓度应保持在１５０～３５０μｇ／Ｌ、１５０～３００μｇ／Ｌ和１００～２００μｇ／Ｌ范围内，可获得最佳疗效而无明显毒性，可视为中国肾移植受者ＣｓＡ的治疗窗。
In this paper, we used fluorescence polarization immunoassay to measure the trough concentration of whole blood CsA12h after oral administration of CsA by specific monoclonal reassociation kit. A total of 314 renal transplantation recipients receiving standard triple immunotherapy (CsA + AZP + Pred) from April 1992 to April 1994 Were studied continuously for 1034 whole blood CsA trough concentrations and the corresponding time of the patient’s serum creatinine, blood urea nitrogen and liver function in order to observe its clinical efficacy and safety, the results suggest that: the standard triple immunotherapy of renal transplant recipients , The best effect of CsA blood concentration should be maintained within 150 ~ 350μg / L, 150 ~ 300μg / L and 100 ~ 200μg / L after 3 months, 3 ~ 6 months and 6 months Without obvious toxicity, it can be regarded as the therapeutic window of CsA in kidney transplant recipients in China.